Soluble Epoxide Hydrolase Inhibitors for Bone Loss Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for periodontitis and related bone loss issues, such as periodontal disease and osteoclastogenesis, are inadequate in addressing the underlying inflammatory responses and bone regeneration, particularly due to the instability and rapid metabolism of epoxyeicosatrienoic acids (EETs) by soluble epoxide hydrolase (sEH).
Innovation Solution
Administration of agents that increase the production and levels of epoxygenated fatty acids, specifically EETs, and inhibitors of soluble epoxide hydrolase (sEH), including nucleic acids like siRNA and pharmacophores like ureas and amides, to stabilize EETs and reduce their metabolism, thereby promoting anti-inflammatory and regenerative effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EETs are administered to treat periodontitis and promote bone regeneration, then anti-inflammatory effects are achieved, but EETs are rapidly metabolized by sEH leading to instability and reduced therapeutic efficacy
Solution Approach 1:
The patent uses sEH inhibitors as intermediary substances that block the metabolism of EETs. By inhibiting the enzyme sEH, the therapeutic effect of EETs is prolonged and enhanced without directly administering unstable EETs. This intermediary approach resolves the contradiction by protecting EETs from rapid degradation.
Solution Approach 2:
The patent changes the biochemical parameter of EET metabolism by introducing sEH inhibitors. This parameter change prevents the rapid conversion of EETs to their inactive metabolites, thereby stabilizing EET levels in the body and maintaining their therapeutic anti-inflammatory effects throughout the treatment period.
2Duration of action of stationary object
If sEH inhibitors are used to stabilize EETs, then EET metabolism is reduced and therapeutic effects are prolonged, but the complexity of treatment increases with multiple agents
Solution Approach 1:
The patent combines sEH inhibitors with existing periodontal treatments, merging multiple therapeutic mechanisms into a coordinated treatment protocol. This allows the prolonged action of EETs to be achieved while integrating the inhibitor therapy with standard dental care practices, managing treatment complexity through systematic combination.
Solution Approach 2:
The sEH inhibitors serve multiple functions: they stabilize EETs, reduce inflammation directly, and prevent the formation of pro-inflammatory metabolites. This multi-functionality reduces treatment complexity by using a single agent to achieve multiple therapeutic goals simultaneously.
3Object-generated harmful factors
If conventional treatments target COX and LOX branches of ARA cascade, then proinflammatory mediators are reduced, but the cytochrome P450 branch producing anti-inflammatory EETs is not adequately exploited
Solution Approach 1:
Instead of only targeting proinflammatory pathways (COX and LOX branches) to reduce harmful effects, the patent inverts the approach by activating and protecting the anti-inflammatory cytochrome P450 branch. By using sEH inhibitors to preserve EETs, the treatment shifts focus from suppressing inflammation to actively promoting anti-inflammatory mechanisms.
Solution Approach 2:
The patent employs a composite therapeutic strategy that targets multiple branches of the ARA cascade simultaneously. By combining COX/LOX inhibition with cytochrome P450 activation and sEH inhibition, the treatment creates a multi-component approach that addresses both proinflammatory and anti-inflammatory pathways, enhancing overall therapeutic versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces bone loss, inhibits osteoclastogenesis, and promotes bone regeneration by stabilizing anti-inflammatory EETs and reducing pro-inflammatory mediator production, offering a therapeutic value in treating periodontitis and related conditions.
Implementation Method 1
All EETs are then further metabolized into less active dihydroxy-eicosatrienoic acids (DHETs) by the enzyme soluble epoxide hydrolase (sEH, EC 3.3.2.10)
Data Source
AI summary
Provided are compositions and methods for preventing, mitigating, decreasing, inhibiting and/or reversing bone loss and/or increasing and/or promoting bone regeneration and remodeling and/or preventing, mitigating, decreasing, inhibiting and/or reversing periodontitis and/or periodontal disease in a subject by administering to the subject an effective amount of an inhibitor of soluble epoxide hydrolase (sEH).